Navigation Links
Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
Date:6/27/2011

was observed in the incidence of withdrawal from the study by any treatment group (placebo and the two arms).

Vaughan Clift, MD, Chief Regulatory Officer of Ampio, clarified that …"Statistical analysis of the IELT results is complex. The patients' IELT distribution is positively skewed (non-normal distribution) and requires specific statistical tests and reporting of results. For example, reporting the average (mean) IELT is an inappropriate estimator of effect size. The median or geometric mean are both generally considered to be more acceptable. Most published studies on PE report either the mean IELT or the geometric mean IELT. We chose to report the medians because a median makes no assumption about the underlying distribution. For the purpose of comparison with other studies on Tramadol and dapoxetine (Priligy®), we also report the mean and the geometric mean of our results. A more recent evidence based definition was published by the International Society for Sexual Medicine (ISSM) in 2010 that defines lifelong PE as: "Ejaculation which always or nearly always occurs prior to or within one minute of vaginal penetration". Over 50% (314 patients) of the patients included in our study met the new clinical criteria."

Don Wingerter, Ampio's CEO noted that ..." We are very pleased with the results of this phase III clinical study which demonstrated both efficacy and no safety concerns for Zertane™ in treating PE.  We are aggressively pursuing regulatory approval for Zertane™ in Europe and are in discussions with potential distribution partners in Europe and Asia.  Equally important, our intellectual property that protects our commercialization of Zertane™ also encompasses combination products which combine Zertane™ with erectile dysfunction drugs (PDE5 inhibitors and others), so we believe our franchise in the clinical field of sexual dysfunction will be expanded."

References

<
'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ampio Pharmaceuticals Set to Join Russell 3000 Index
2. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
3. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
4. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
5. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
6. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
7. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
8. Kaiser Permanente Recognized as a J.D. Power 2011 Customer Service Champion
9. CHAMPION Study Published in The Lancet
10. Champions CFO Resigns
11. Champions Biotechnology Awarded $1.46 million in Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... DIEGO , July 30, 2014   ... biotech company that designs and develops novel diagnostics ... of cancer, announced today the completion of a ... financing included new investors RusnanoMedInvest (RMI) and Arcus ... and Pfizer Venture Investments, as well as undisclosed ...
(Date:7/30/2014)... , 30. Juli 2014 ... ein führender Anbieter im Bereich Atemtherapie- und ... des Landgerichts München in Deutschland anfechten werden. ... bestimmten Masken ein Patent von ResMed verletze. ... in wichtigen Ländern gegen verschiedene Patente von ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today ... Key results include: , Total revenues increased 11 ... growth driven by strong performance across the portfolio, particularly ... ® (denosumab) and XGEVA ® (denosumab). ... by higher revenues and a significant increase in the ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
... SUNNYVALE, Calif., Dec. 28, 2010 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that its president and chief executive officer, ... 29th Annual J.P. Morgan Healthcare Conference in San Francisco on ... A live webcast of the presentation will be ...
... Medical Group Inc. (Nasdaq: WWIN ), ("Winner ... and non-woven fabric made from 100% natural PurCotton® products ... was recently held by Winner Medical and Cotton Incorporated ... in a high footprint shopping mall in Shanghai. ...
Cached Medicine Technology:Accuray Incorporated's CEO to Speak at 29th Annual J.P. Morgan Healthcare Conference 2Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 2Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 3Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 4
(Date:7/30/2014)... 30, 2014 Decene is an ... chain of ten carbon atoms with one double ... of 1-decenes. It can be used as a ... to produce epoxides, amines, oxo alcohols, synthetic lubricants, ... Early buyers will receive 10% customization on this ...
(Date:7/30/2014)... 2014 Naomi Fried, PhD, and ... of Directors of the American Telemedicine Association (ATA). ... which has a mission to promote professional, ethical ... and information technology. , “Both Naomi Fried and ... extraordinary expertise and are well known experts in ...
(Date:7/30/2014)... 2014 (HealthDay News) -- Clues to whether a person is ... test, a new study suggests. Chemical changes to a ... help spur suicidal thoughts and behaviors, the study,s authors explained. ... doctors to a patient,s risk for suicide, they said. ... have been stymied in our prevention efforts because we have ...
(Date:7/30/2014)... 2014 The global digital pathology market was ... expected to grow at a CAGR of 11.8%, to reach ... digital pathology is growing and is expected to continue to ... scanners and image analysis software enable pathologists to be efficient ... In 2013, the North American market was valued at $128.9 ...
(Date:7/30/2014)... This news release is available in French . ... Inserm, led by Claude Gronfier (Inserm Unit 846: Stem ... conducted a study under real conditions on the body ... Concordia. The researchers have shown that a particular kind ... biological rhythms are correctly synchronised despite the absence of ...
Breaking Medicine News(10 mins):Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Dimly lit working environments: Correcting your body clock is possible! 2Health News:Dimly lit working environments: Correcting your body clock is possible! 3Health News:Dimly lit working environments: Correcting your body clock is possible! 4
... impairment that strikes in the early stages of prion diseases such ... ,The findings suggest there may be a way to cure ... before it has time to kill off large numbers of brain ... lives of 158 people in Britain, and seven more are known ...
... recently discovered genes from an ancient wheat variety have led ... ,In a recent set of papers published in the ... as Nax1 and Nax2. The genes work by excluding salt ... the other from the leaves. The discovery of the two ...
... is a neighborhood which renders immense potential to walk around, ... revealed in a survey conducted by// Ethan Berke of Dartmouth ... for publication in the March issue of American Journal of ... group of 65-97. Some of the parameters that were analyzed ...
... more slowly in women and older adults, a new study at ... to the skin heal more quickly in women than in men, ... inside the mouth," said Dr. Phillip Marucha, head of periodontics at ... of age, men's mouth wounds heal faster than women's." ...
... practice guidelines for diagnosis and management of venous thromboembolism.// ... clotting in the veins. ,Key elements of ... rules to establish pretest probability of deep vein thrombosis ... and the utility of various diagnostic tools such as ...
... the application filed before the Hon’ble Supreme Court, the ... to ST candidates in the All India Quota seats ... session 2007-08. While disposing of this application for directions ... case Vs Union of India, WP 18/2006, Hon’ble Supreme ...
Cached Medicine News:Health News:Researchers Make Strides in VCJD Detection 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2Health News:Oral Wounds Heal Slower in Women, Older Adults 2Health News:New Guidelines for Diagnosis of Venous Thromboembolism 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Medicine Products: